Journal of Immunotherapy and Precision Oncology

Aims & Scope

JIPO publishes high-quality manuscripts related to the field of immunotherapy and precision oncology.

The content appeals to a broad readership of healthcare professionals and scientists, especially those with an interest in oncology and immunology.

The scope of the Journal includes translational science and preclinical and clinical medicine.

Article types include original research articles, brief reports of new research, comprehensive review articles and meta-analyses, case reports, and more.

Manuscripts related to preclinical, clinical, and translational discoveries related with immunity and cancer and immunotherapy, such as new discoveries about immune system function and biology, new therapeutic approaches to different malignancies, mechanisms of resistance, clinical assessment, and more will be considered for publication.

Subjects related to precision oncology including prognostic or predictive markers and innovative targeted therapy advances in diagnostic technology will also be considered.

High quality evidence-based guidelines of credible professional entities will also be considered for publication.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology, Immunology and Microbiology and Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Biochemistry, Genetics and Molecular Biology, Immunology and Microbiology and Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 2,400.00 USD. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review

  Citation: 97

  Authors: Kavanya, Gerald S.

• Clinical Development of Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors

  Citation: 45

  Authors: Chia-Chi

• B7-H3 Inhibitors in Oncology Clinical Trials: A Review

  Citation: 40

  Authors: Kavanya, Jared, Gerald S.

• The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients’ Outcomes

  Citation: 39

  Authors: Hamzah, Tenglong, Faisal Shaukat, Daniel Hartman, Wei, Adi, Yinghong

• Extracellular Signal-Regulated Kinase (ERK) Inhibitors in Oncology Clinical Trials

  Citation: 35

  Authors: Haelee M, David K, Gerald S

• Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab

  Citation: 25

  Authors: Fadi, Naval

• Being Realistic and Optimistic in Curing Cancer

  Citation: 22

  Authors: Aung

• Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review

  Citation: 22

  Authors: Shruthi Harish, Nita, Andrew G., Dan S., Nagham

• Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy

  Citation: 22

  Authors: Nicholas J., Ryosuke, Meagan, Jacob J., Aaron M., Razelle

• Highlights on Ocular Toxicity of Immune Checkpoint Inhibitors at a US Tertiary Cancer Center

  Citation: 22

  Authors: Anam A., Andrew T., Dan S., Nimisha, Azadeh, Amina L., Nagham S.